Retina

Dinah Zur, MD, shares insights from her International SPECTRALIS Symposium lecture

Robyn Guymer, AM, MBBS, PhD, FRANZCO, FAHMS, presented two studies involving the EZ line at this year’s International SPECTRALIS Symposium

Ophthalmologists may be “at the forefront of a revolution in healthcare,” the nephrology professor said at this year’s International SPECTRALIS Symposium

The new technology will be crucial to imaging retinal function in the future, Prof Hüttmann predicted at the International SPECTRALIS Symposium

Prof Hogg presented a wide breadth of research at the International SPECTRALIS Symposium

Brazilian ANVISA has granted marketing authorisation for FYB201 (Ranivisio), a biosimilar to Lucentis.

Long-term benefits and vision preservation using an extended macular vision IOL

The therapy planning support tool has been trained on thousands of patient cases from more than 200 retina centres throughout Europe

Lysine, proline and arginine levels progressively increased from non-proliferative DR to proliferative DR stages

Vitamins B6, B9 and B12 were found to be neuroprotective against retinal ganglion cell death

The OCT platform offers deep imaging depth, rapid sweeping speed, extensive scan range, accurate results and multimodal imaging capabilities

The company shared results from the AAVB-081 clinical programme and AAVB-039 preclinical programme at ARVO

The biomarkers are especially crucial for patients with lupus nephritis

Utilizing artificial intelligence (AI), Cascader is a new medical technology company that aims to transform the detection and management of eye disease.

LuxIA is designed to screen adult diabetic patients for more-than-mild diabetic retinopathy.

Topcon Healthcare has appointed Daniela Ferrara, MD, PhD, as chief medical officer to lead the company’s clinical and medical strategy

The US FDA recently approved revakinagene taroretcel-lwey (ENCELTO) for the treatment of idiopathic macular telangiectasia type 2 (MacTel)

The US Food and Drug Administration did not identify any safety or efficacy issues associated with aflibercept 8 mg

The study aimed to clarify how race affects visual outcomes for patients with diabetic macular oedema treated with ranibizumab

The phase 3 LUCERNE and TENAYA trials suggested that faricimab may allow clinicians to extend the interval between injections to up to 16 weeks after an initial loading phase

In an established animal model of age-related macular degeneration, Eleva’s recombinant human CPV-104 improved two hallmarks of the disease

Alcon acquired the historic ophthalmic instrument company in 2000

Bangalore-based Eyestem will share more research findings on Eyecyte-RPE at this year's Association for Research in Vision and Ophthalmology meeting

The company's therapeutic candidates include a bispecific antibody to target vascular retinal diseases

In the European Union and the United Kingdom, aflibercept 8 mg (Eylea HD in the US) is currently approved for neovascular age-related macular degeneration and diabetic macular oedema

Fundus images of diabetic retinopathy were assessed by general ophthalmologists, retina specialists and the Aireen artificial intelligence system

The Congress on Controversies in Ophthalmology highlights debates, but also discussions

Retina topics serve as the backbone of the scientific programme at this year’s Congress on Controversies in Ophthalmology

Regulatory agencies issued approvals for new treatments and expanded uses of existing therapies in the retina space

Both trials failed to meet their primary endpoints for treatment of age-related macular degeneration